Vivus: Former AstraZeneca Executive Fante to Advise on Qsymia

Wall Street Journal | Tue, 07 May 2013 05:03:28 -0700

"With the recent FDA approval of the REMS modification for Qsymia, and more payors recognizing medical-obesity treatment, Vivus is making significant progress on its commercialization strategies," said Vivus Chief Executive Leland Wilson. "We are ...

Weight Loss Isn't Just for Looking Good Anymore

Motley Fool | Wed, 15 May 2013 16:04:29 -0700

After getting rejected once, Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and VIVUS' (NASDAQ: VVUS ) Qsymia were both approved by the FDA last year. And the FDA seems open to approving a third drug, Orexigen's (NASDAQ: OREX ) Contrave.

VIVUS Mails Letter to Stockholders Providing Business Update

MarketWatch (press release) | Mon, 13 May 2013 04:06:34 -0700

In mid-April, VIVUS successfully achieved another major milestone in our ongoing commercialization efforts with FDA approval of our Risk Evaluation and Mitigation Strategy (REMS) modification for Qsymia. This approval will allow patients to access ...

Tracking progress of new diet drug Qsymia

WPEC | Mon, 06 May 2013 15:20:24 -0700

CLICK HERE for more information on Boca Health · CLICK HERE for more information on diet drug Qsymia. We introduced you to Pamela Eidelberg in March when she lost 32 pounds on Qsymia the first new diet drug approved by the FDA in over a decade.

WPEC